HSGX - ヒストジェニックス （Histogenics Corporation） ヒストジェニックスHSGXのチャート
HSGXの企業情報
| symbol | HSGx |
|---|---|
| 会社名 | Histogenics Corp （ヒストジェニックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Industrial Specialties |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company''s product candidate NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics specifically cartilage damage in the knee. NeoCart is a cartilage-like implant created using a patient''s own cartilage cells through a series of tissue engineering processes. The patient''s cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient the cell- and scaffold construct undergoes a bioengineering process in the Company''s Tissue Engineering Processor (TEP). The Company has operations in the United States and Israel. ヒストジェニックスは、米国の再生医療企業。市場の筋骨格分野向けの製品の開発および商業化に従事。細胞療法と組織工学技術を組み合わせ、軟骨由来の特定の痛みと不動状態にある患者に焦点を当てた組織の修復・再生のための製品を開発する。膝軟骨損傷の治療用NeoCartのほか、軟骨損傷を防止する技術と製品の開発手掛ける。 Histogenics Corp. engages in the development, marketing, and commercialization of restorative cell therapies. Its regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives, and growth factors to provide solutions that can be utilized individually and in concert to treat musculoskeletal-related conditions. The company was founded on June 28, 2000 and is headquartered in Waltham, MA. |
| 本社所在地 | 830 Winter Street 3rd Floor Waltham MA 02451 USA |
| 代表者氏名 | Garheng Kong Garheng Kong |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 781-457-7900 |
| 設立年月日 | 36678 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2014年 |
| 従業員数 | 45人 |
| url | www.histogenics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/hsgx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -23.97800 |
| 終値（lastsale） | 0.584 |
| 時価総額（marketcap） | 16814238.336 |
| 時価総額 | 時価総額（百万ドル） 39.87468 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 31.10268 |
| 当期純利益 | 当期純利益（百万ドル） -27.48600 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Histogenics Corp revenues was not reported. Net loss increased 37% to $18.6M. Higher net loss reflects Change in fair value of warrant liabilit increase from $404K to $5.3M (expense) Interest Income (expense) net decrease of 8% to $69K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.62 to -$0.67. |
HSGXのテクニカル分析
HSGXのニュース
Ocular Biotechs Histogenics (NASDAQ:HSGX), Ocugen Announce Stock-For-Stock Merger 2019/04/08 12:48:00 Benzinga
Histogenics Corporation (NASDAQ: HSGX) and privately held Ocugen announced a merger Monday that will create a new, Nasdaq-listed company aiming …
Helius Medical: A Failed Clinical Trial, Redacted Data, And Questionable Leadership, Points To An Ineffective Device 2019/01/29 10:00:00 Seeking Alpha
Ocular Biotechs Histogenics (NASDAQ:HSGX), Ocugen Announce Stock-For-Stock Merger 2019/04/08 12:48:00 Benzinga
Histogenics Corporation (NASDAQ: HSGX) and privately held Ocugen announced a merger Monday that will create a new, Nasdaq-listed company aiming …